Ismaeel Ebrahim1, Gary Maartens1,2, Lubbe Wiesner1, Catherine Orrell3, Wynand Smythe4, Helen McIlleron1,2. 1. Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa. 2. Wellcome Centre for Infectious Diseases Research in Africa (CIDRI-Africa), Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa. 3. Desmond Tutu HIV Centre, Institute of Infectious Diseases and Molecular Medicine (IDM) and Department of Medicine, University of Cape Town, Cape Town, South Africa. 4. Clinical Research Centre, University of Cape Town, Cape Town, South Africa.
Abstract
BACKGROUND: Darunavir/ritonavir is better tolerated than lopinavir/ritonavir and has a higher genetic barrier to resistance. Co-administration with rifampicin has been contraindicated as a significant reduction in darunavir exposure is expected. This is a barrier to darunavir/ritonavir use where TB is endemic. OBJECTIVES: To evaluate the safety and pharmacokinetic profile of adjusted doses of darunavir/ritonavir with rifampicin. METHODS: Virally suppressed participants on second-line lopinavir/ritonavir-based ART were switched to darunavir/ritonavir 800/100 mg q24h. In sequence: rifampicin was added; the dose of ritonavir was escalated; and darunavir was increased (darunavir/ritonavir 1600/200 mg q24h and 800/100 mg q12h were given in randomized sequence with rifampicin). Darunavir plasma concentrations were measured on the seventh/last day of each treatment period. To prevent viral rebound, dolutegravir (50 mg q12h) was added during rifampicin administration and for 1 week thereafter. Clinical events, ALT and bilirubin were monitored every 2-3 days during rifampicin administration. RESULTS: A total of 17/28 participants started study treatment. Six (35.3%) were withdrawn for symptomatic hepatitis with severe ALT elevations, developing after 9-11 days of rifampicin and 2-4 days of ritonavir 200 mg. The study was stopped prematurely due to this high rate of hepatotoxicity. Only four participants completed the study. All hepatotoxicity resolved on withdrawal of study treatment. All participants were successfully re-established on their lopinavir/ritonavir-based regimen. After doubling the darunavir/ritonavir doses on rifampicin, darunavir pre-dose concentrations approached those on standard doses without rifampicin for q12h doses, but not for q24h doses. CONCLUSIONS: Adjusted doses of darunavir/ritonavir with rifampicin had unacceptable risk of hepatotoxicity. Darunavir trough concentrations were markedly reduced with the daily adjusted dose.
BACKGROUND: Darunavir/ritonavir is better tolerated than lopinavir/ritonavir and has a higher genetic barrier to resistance. Co-administration with rifampicin has been contraindicated as a significant reduction in darunavir exposure is expected. This is a barrier to darunavir/ritonavir use where TB is endemic. OBJECTIVES: To evaluate the safety and pharmacokinetic profile of adjusted doses of darunavir/ritonavir with rifampicin. METHODS: Virally suppressed participants on second-line lopinavir/ritonavir-based ART were switched to darunavir/ritonavir 800/100 mg q24h. In sequence: rifampicin was added; the dose of ritonavir was escalated; and darunavir was increased (darunavir/ritonavir 1600/200 mg q24h and 800/100 mg q12h were given in randomized sequence with rifampicin). Darunavir plasma concentrations were measured on the seventh/last day of each treatment period. To prevent viral rebound, dolutegravir (50 mg q12h) was added during rifampicin administration and for 1 week thereafter. Clinical events, ALT and bilirubin were monitored every 2-3 days during rifampicin administration. RESULTS: A total of 17/28 participants started study treatment. Six (35.3%) were withdrawn for symptomatic hepatitis with severe ALT elevations, developing after 9-11 days of rifampicin and 2-4 days of ritonavir 200 mg. The study was stopped prematurely due to this high rate of hepatotoxicity. Only four participants completed the study. All hepatotoxicity resolved on withdrawal of study treatment. All participants were successfully re-established on their lopinavir/ritonavir-based regimen. After doubling the darunavir/ritonavir doses on rifampicin, darunavir pre-dose concentrations approached those on standard doses without rifampicin for q12h doses, but not for q24h doses. CONCLUSIONS: Adjusted doses of darunavir/ritonavir with rifampicin had unacceptable risk of hepatotoxicity. Darunavir trough concentrations were markedly reduced with the daily adjusted dose.
Authors: Hanneke M J Nijland; Rafaëlla F A L'homme; Gerard A Rongen; Peter van Uden; Reinout van Crevel; Martin J Boeree; Rob E Aarnoutse; Peter P Koopmans; David M Burger Journal: AIDS Date: 2008-05-11 Impact factor: 4.177
Authors: Vanitha Sekar; Sabrina Spinosa-Guzman; Els De Paepe; Tanja Stevens; Frank Tomaka; Martine De Pauw; Richard M W Hoetelmans Journal: Clin Pharmacokinet Date: 2010-05 Impact factor: 6.447
Authors: Bianca S Buijs; Guido E van den Berk; Charlotte P Boateng; Andy I Hoepelman; Erik M van Maarseveen; Joop E Arends Journal: AIDS Date: 2015-04-24 Impact factor: 4.177
Authors: C J L la Porte; E P H Colbers; R Bertz; D S Voncken; K Wikstrom; M J Boeree; P P Koopmans; Y A Hekster; D M Burger Journal: Antimicrob Agents Chemother Date: 2004-05 Impact factor: 5.191
Authors: David W Haas; Susan L Koletar; Laura Laughlin; Michelle A Kendall; Carol Suckow; John G Gerber; Andrew R Zolopa; Richard Bertz; Michael J Child; Lara Hosey; Beverly Alston-Smith; Edward P Acosta Journal: J Acquir Immune Defic Syndr Date: 2009-03-01 Impact factor: 3.731
Authors: Richard A Murphy; Vincent C Marconi; Rajesh T Gandhi; Daniel R Kuritzkes; Henry Sunpath Journal: PLoS One Date: 2012-09-28 Impact factor: 3.240
Authors: Michelle A Kendall; Umesh Lalloo; Courtney V Fletcher; Xingye Wu; Anthony T Podany; Sandra W Cardoso; Prudence Ive; Constance A Benson Journal: Clin Infect Dis Date: 2021-08-16 Impact factor: 20.999
Authors: Amedeo De Nicolò; Andrea Calcagno; Ilaria Motta; Elisa De Vivo; Antonio D'Avolio; Giovanni Di Perri; Lubbe Wiesner; Isma-Eel Ebrahim; Gary Maartens; Catherine Orrell; Helen McIlleron Journal: Antimicrob Agents Chemother Date: 2022-05-18 Impact factor: 5.938
Authors: Tom G Jacobs; Elin M Svensson; Victor Musiime; Pablo Rojo; Kelly E Dooley; Helen McIlleron; Rob E Aarnoutse; David M Burger; Anna Turkova; Angela Colbers Journal: J Antimicrob Chemother Date: 2020-12-01 Impact factor: 5.790